Literature DB >> 23519388

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.

T Schroeder, J Fröbel, R-P Cadeddu, A Czibere, A Dienst, U Platzbecker, G Bug, L Uharek, R Fenk, U Germing, N Kröger, R Haas, G Kobbe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23519388     DOI： 10.1038/leu.2013.64

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  27 in total

1.  Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects.

Authors:  Grégory Ehx; Gilles Fransolet; Laurence de Leval; Stéphanie D'Hondt; Sophie Lucas; Muriel Hannon; Loïc Delens; Sophie Dubois; Pierre Drion; Yves Beguin; Stéphanie Humblet-Baron; Frédéric Baron
Journal:  Oncoimmunology       Date:  2017-04-12       Impact factor: 8.110

2.  A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Authors:  Sarah Nikiforow; Haesook T Kim; Heather Daley; Carol Reynolds; Kyle Thomas Jones; Philippe Armand; Vincent T Ho; Edwin P Alyea; Corey S Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

3.  Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.

Authors:  J El-Cheikh; R Massoud; E Fares; N Kreidieh; R Mahfouz; M Charafeddine; M A Kharfan-Dabaja; A Bazarbachi
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

Review 4.  Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?

Authors:  F Lussana; M Di Ianni; A Rambaldi
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

Review 5.  The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.

Authors:  Sarah A Wall; Steven Devine; Sumithira Vasu
Journal:  Blood Rev       Date:  2017-07-15       Impact factor: 8.250

Review 6.  Hypomethylating agents after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Guido Kobbe
Journal:  Stem Cell Investig       Date:  2016-11-28

Review 7.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

8.  Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Charles Craddock; Myriam Labopin; Marie Robin; Juergen Finke; Patrice Chevallier; Ibrahim Yakoub-Agha; Jean Henri Bourhis; Henrik Sengelov; Didier Blaise; Thomas Luft; Michael Hallek; Nicolaus Kröger; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

9.  Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Authors:  Iskra Pusic; Jaebok Choi; Mark A Fiala; Feng Gao; Matthew Holt; Amanda F Cashen; Ravi Vij; Camille N Abboud; Keith E Stockerl-Goldstein; Meghan A Jacoby; Geoffrey L Uy; Peter Westervelt; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-05       Impact factor: 5.742

10.  Impact of 5-aza-2'-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells.

Authors:  Jan Kehrmann; Roman Tatura; Michael Zeschnigk; Michael Probst-Kepper; Robert Geffers; Joerg Steinmann; Jan Buer
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.